

****Published April 2013****

MarketVIEW: Typhoid travel vaccines (CAT: VAMV046)

Product Name	:	MarketVIEW: Typhoid travel vaccines
Description	:	Global vaccine commercial opportunity assessment
Contents	:	Executive presentation + 1 forecast model
Therapeutic Area	:	Travel vaccines
Publication date	:	April 2013
Catalogue No	:	VAMV046

Background

Typhoid fever is caused by *Salmonella typhi* bacteria that are transmitted through contaminated food and drink in conditions of poor sanitation. Without prompt treatment with antibiotics typhoid fever can cause serious complications and even death. It is estimated in the developing world that typhoid fever affects around 21.5 million persons each year.

Travellers to typhoid endemic countries are recommended to be vaccinated at least two weeks before departure. There are two main typhoid vaccines available: Crucell/J&J's oral Vivotif and Sanofi's Typhim Vi. Typhoid vaccines are not widely used in the public sector in endemic countries.

This **MarketVIEW** product contains a comprehensive MS Excel-based model + summary presentation which forecasts the potential commercial value of typhoid vaccines in the travelling populations from major Western¹ markets until 2030. The model contains value (\$ m) and volume (mio doses) predictions per product type along with timeframe, pricing and penetration estimates for all target populations. Coverage of commercial typhoid vaccine sales and supply is also included.

¹ US, Canada, Australia, UK, France, Italy, Germany, Spain and other EU



Methodology

VacZine Analytics has closely monitored all significant source material pertaining to typhoid vaccines. Source materials used are literature articles, government websites, medical bodies and associations, conference proceedings etc. Previously published research by **VacZine Analytics** in the field of travel vaccines has also been utilised.

PRODUCT CONTENTS:

Published April 2013 (CAT No: VAMV046)

****This product is composed of two forecast models and a summary presentation

Author's note
Executive Summary
Commercial model: key model outputs
Typhoid vaccines: total revenues
Typhoid vaccines: revenues by vaccine
Vivotif: revenues by country
Typhoid vaccines: volume by vaccine
Typhoid vaccines: key assumptions
Commercial model assumptions
Markets modelled to 2030
Typhoid vaccine market shares
Key model imports: travel behaviour assumptions
Typhoid vaccines: backup/source material
Background to typhoid fever
Travel associated typhoid fever
Typhoid vaccination recommendations
Types of typhoid vaccines
US dosage and schedule for typhoid vaccines
Producers of Vi typhoid vaccine
Typhoid vaccine sales and supply
Crucell, Vivotif
WHO global typhoid vaccine sales volume
Sanofi: Typhim Vi
Bibliography
About **VacZine Analytics**
Disclaimer

PAGES: ~29 MS PowerPoint slides, fully referenced/sourced. Available in .pdf form

Contents – Vaccine demand model PX vaccine (MS Excel-based)

Title sheet
CHARTS – VALUE
CHARTS – VOLUME
Value
Volume
Country worksheets →



Continued...

US
Canada
France
Germany
Italy
Spain
UK
Other Europe
Australia
Source material →
Travel market variables
Global price summary
Trips to high-risk typhoid endemic countries
Trips to moderate risk typhoid endemic countries
Back page

Worksheets = 32 interconnected

PRODUCT COST:

VacZine Analytics will grant a [enter region] license to [enter client name], for the price of:

- o USD \$4995.00/ GBP £3330.00[#] (Region license)*

*A region is North America, Europe or ROW


For orders in the UK, VAT at 20% will be added to final invoice total

- indicative prevailing rate will be applied on date of transaction

HOW TO ORDER:

To order please contact your region account manager or order direct at orders@vaczine-analytics.com

This report can also be purchased on-line. Please review the **TERMS and CONDITIONS** of purchase.



VacZine Analytics (R) is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

VacZine Analytics (R) and the “spiral logo” are UK Registered Trademarks, 2009

BIBLIOGRAPHY

1. World Tourism Organisation (WTO). Available at: <http://www.e-unwto.org>. Accessed March 2013
2. Connor BA, Jacobs RJ, Meyerhoff AS. Hepatitis B risks and immunization coverage among American travelers. *J Travel Med*. 2006 Sep-Oct;13(5):273-80
3. Leggat PA et al. Hepatitis B risks and immunisation coverage amongst Australians travelling to southeast Asia and east Asia. *Travel Med Infect Dis*. 2009 Nov;7(6):344-9.
4. Zuckerman JN, Hoet B. Hepatitis B immunisation in travelers: poor risk perception and inadequate protection. *Travel Med Infect Dis*. 2008 Sep;6(5):315-20.
5. Lopez-Velez R et al. Spanish travelers to high-risk areas in the tropics: airport survey of travel health knowledge, attitudes, and practices in vaccination and malaria prevention. *J Travel Med*. 2007 Sep-Oct;14(5):297-305.
6. Heywood AE et al. A cross-sectional study of pre-travel health-seeking practices among travelers departing Sydney and Bangkok airports. *BMC Public Health*. 2012 May 2;12:321.
7. Abbreviated Draft Typhoid Background Paper version 7 (September 30, 2007). Available at: www.who.int/.../SAGE_Background_publicpaper_typhoid_newVaccines.pdf. Accessed: March 2013.
8. Buckle GC et al. Typhoid fever and paratyphoid fever: Systematic review to estimate global morbidity and mortality for 2010. *J Glob Health*. 2012 Jun;2(1):10401
9. Crump JA et al. The global burden of typhoid fever. *Bull World Health Organ*. 2004 May;82(5):346-53.
10. Ekdahl K et al. Risk of travel-associated typhoid and paratyphoid fevers in various regions. *J Travel Med*. 2005 Jul-Aug;12(4):197-204.
11. Lynch MF et al. Typhoid fever in the United States, 1999-2006. *JAMA*. 2009 Aug 26;302(8):859-65.
12. Yung A, Ruff T, Torres J, et al. *Manual of travel medicine: a pre-travel guide for health care practitioners*. 2nd edn. Melbourne: IP Communications, 2004.
13. Typhoid fever – Vaccination. Available at: <http://www.nhs.uk/Conditions/Typhoid-fever/Pages/Prevention.aspx>. Accessed: March 2013.
14. Typhoid & Paratyphoid Fever. Available at: <http://wwwnc.cdc.gov/travel/yellowbook/2012/chapter-3-infectious-diseases-related-to-travel/typhoid-and-paratyphoid-fever.htm>. Accessed: March 2013.
15. Johnson KJ et al. From the CDC: new country-specific recommendations for pre-travel typhoid vaccination. *J Travel Med*. 2011 Nov-Dec;18(6):430-3.
16. Country Information. Mexico. Available at: http://www.nathnac.org/ds/c_pages/country_page_mx.htm. Accessed: March 2013.
17. CDC Yellowbook. Typhoid & Paratyphoid Fever. Available at: <http://wwwnc.cdc.gov/travel/yellowbook/2012/chapter-3-infectious-diseases-related-to-travel/typhoid-and-paratyphoid-fever.htm>. Accessed: March 2013.
18. Crucell Announces Acquisition of Berna Products Corp. from Acambis. Available at: investors.crucell.com/C/132631/PR/200610/1078727_5_6.html. Accessed: March 2013.
19. Acambis buys a sales, distribution division in Berna Products Corp. Aug 25, 2003. Available at: <http://www.bizjournals.com/boston/blog/mass-high-tech/2003/08/acambis-buys-a-sales-distribution-division.html>. Accessed: March 2013.
20. Typhoid vaccine failure warning. 08 October 2012. Available at: <http://www.bbc.co.uk/news/health-19873171> Accessed: March 2013
21. Supply crisis sparked by manufacturer's recall – 700,000 people already injected could be affected. <http://www.guardian.co.uk/travel/2012/dec/25/typhoid-vaccine-shortage-holiday-risk>. Accessed: March 2013.
22. Typhoid and hep A vaccines. Available at: <http://immunisation.dh.gov.uk/vu-193-sept-12>. Accessed: March 2013.

TERMS and CONDITIONS:

VacZine Analytics – a trading division of Assay Advantage Ltd UK Company Number: 5807728 (Herein referred to as “The Company”). (Herein [enter client name] to as “The Client”).

1. This finished research product is provided as a Service. Any additional Service required by the client will be subject to a new proposal being prepared.
2. The Service will commence after written (e-mail) or Fax confirmation stating the Client's acceptance of the Service according to the description proposed by the Company.
3. **Cancellation policy.** The Company's cancellation policies are in accordance with the EU Consumer Protection (Distance Selling) Regulations 2000 (DSRs). Prior to acceptance of an order the Company will make available written information regarding Clients cancellation rights. This is posted on the Company website and is available for public review.
4. **Cancellation rights:** For finished documents - a Client's cancellation rights will last for **seven working days** counting from the day that the order was concluded. If the Services i.e. provision of the documents has taken place with the Client's agreement before this period the Client's cancellation rights have ended.
5. Invoicing will **100%** after submission of deliverables to the Client in a form reasonably acceptable to the Client.
6. If not purchased on line invoices are payable within **thirty days** of the invoice date.
7. All proposals are quoted in **\$USD dollars or £GBP** and invoices are to be settled in the same currency.
8. The Company agrees not to disclose to any third party confidential information acquired in the course of providing the services listed without the prior written consent of the Client. Exception occurs when the information is already in the public domain or when disclosure is necessary to help the Company's employees and agents with the performance of the Company's obligations to achieve satisfactory completion of the project and approved in writing by the Client.
9. **Force Majeure:** The Company will not be liable for any delay or failure to perform any obligation under this Agreement insofar as the performance of such obligation is prevented by an event beyond our reasonable control, included by not limited to, earthquake, fire, flood or any other natural disaster, labour dispute, riot, revolution, terrorism, acts of restraint of government or regulatory authorities, failure of computer equipment and failure or delay of sources from which data is obtained.
10. Please also refer to Master **TERMS and CONDITIONS** available upon request.

VacZine Analytics

Warren House
Bells Hill
Bishops Stortford
Herts
CM23 2NN
United Kingdom
Tel: +44 (0) 1279 654514 / +44 (0) 7952470582 / Fax: +44 (0) 1279 655926
E-mail: info@vacZine-analytics.com



VacZine Analytics®
Bringing life to vaccine strategy...

About VacZine Analytics:

VacZine Analytics is an established strategic research agency based in the United Kingdom. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new vaccines and biologics.

For more information please visit our website www.vacZine-analytics.com

VacZine Analytics (R) is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

VacZine Analytics (R) and “the spiral logo” are UK Registered Trademarks, 2009